Elicio Therapeutics (ELTX) vs Talphera (TLPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Talphera (TLPH) has outperformed Elicio Therapeutics (ELTX) over the past year, losing 41.4% versus a loss of 82.8%. Over five years, TLPH leads with a -94.0% price change compared with -96.1% for ELTX. Elicio Therapeutics is the larger company by market cap ($41.0 million vs $40.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELTX | TLPH |
|---|---|---|
| Share price | $1.45 | $0.7852 |
| Market cap | $41.05M | $40.80M |
| 1-day change | -3.33% | +6.25% |
| YTD return | -81.78% | -31.12% |
| 1-year return | -82.84% | -41.40% |
| 5-year return | -96.13% | -93.96% |
| EPS (TTM) | $-1.81 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $28.00K |
| Net income (latest FY) | $-39.57M | $-14.29M |
| Operating margin | — | -48157.14% |
| Net margin | — | -51035.71% |
| 52-week high | $16.00 | $1.57 |
| 52-week low | $1.25 | $0.69 |
| Distance from 52-week high | -90.94% | -49.99% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +842.76% | +298.62% |
| Average volume | 324.71K | 144.13K |
| Shares outstanding | 28.31M | 51.96M |
| Employees | 33 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLPH has outperformed ELTX by 41.4 percentage points over the past year.
About Elicio Therapeutics
ELTX stock →Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About Talphera
TLPH stock →Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
ELTX vs TLPH FAQ
Which is bigger, Elicio Therapeutics or Talphera?
Elicio Therapeutics (ELTX) is larger, with a market capitalization of $41.05M compared with $40.80M for Talphera (TLPH).
Which stock has performed better over the past year, ELTX or TLPH?
TLPH returned -41.40% over the past 12 months, compared with -82.84% for ELTX (price return, excluding dividends). Past performance does not predict future results.
Are Elicio Therapeutics and Talphera in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.